Recent News

• 12.08.2025 - A Phase 1, Multicenter, Randomized, Placebo-Controlled Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of AMX0114 in Amyotrophic Lateral Sclerosis (LUMINA)
• 12.08.2025 - Characterizing the CSF Biomarker Signature of Calpain-2 Activity in ALS and Its Application in the Phase 1 LUMINA Trial
• 10.09.2025 - Maria and Kelly Story
• 10.08.2025 - Update on the Phase 2b Portion of the ORION Trial in Progressive Supranuclear Palsy (PSP)
• 10.07.2025 - Presentation: Characterizing the CSF Biomarker Signature of Calpain-2 Activity in ALS and the Biomarker Impact of Calpain-2 Inhibition in a Preclinical Model of ALS
• 10.07.2025 - Poster: Characterizing the CSF Biomarker Signature of Calpain-2 Activity in ALS and the Biomarker Impact of Calpain-2 Inhibition in a Preclinical Model of ALS
• 10.07.2025 - LUMINA Study Update

Recent Filings

• 12.03.2025 - 4 Statement of changes in beneficial ownership of securities
• 12.01.2025 - 144 Report of proposed sale of securities
• 11.17.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 11.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 11.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 11.13.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 11.06.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 11.06.2025 - 8-K Current report
• 11.06.2025 - EX-99.1 EX-99.1
• 10.30.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors